Recurrent or metastatic cervical cancer (RMCC) remains one of the most challenging malignancies to treat, with median overall survival rarely exceeding 13 to 17 months despite recent advances. Since ...

Booking Health, a global medical travel provider, announced today the release of its 2026 report on advanced head and neck ...

First approved by the US FDA in 2014 for advanced skin cancer, Keytruda is now used globally for certain lung cancers, ...

The FDA and Corbus Pharmaceuticals Holdings, Inc., have agreed on second-line registrational study designs evaluating CRB-701 ...

A new study co-led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center has found that women with early-stage cervical cancer who received radiation plus chemotherapy reported a ...

Despite advances in prevention with immunization and screening processes, cervical cancer remains a significant source of morbidity and mortality throughout the world, particularly in areas where ...

Integrative analysis of VB10.16 and atezolizumab in advanced HPV16-positive cervical cancer: Linking biomarker insights to clinical outcomes. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...